NoneIncrease
Activities of daily living
Dulaglutide → Activities of daily living
Dulaglutide → Activities of daily living
Evidence profile
NoneIncreasePatient-Reported
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Higher dulaglutide doses improve weight loss in type 2 diabetes
Key finding
Weight decreased by 3.1 kg (p = 0.001)
The AWARD-11 trial compared the effects of Dulaglutide 3.0 mg and 4.5 mg to 1.5 mg on body weight in patients with type 2 diabetes, finding significant weight reductions.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Long-Term (1–5 y)
High bias
Last updated July 5, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Dulaglutide 1.5 mg, Dulaglutide 3.0 mg, Dulaglutide 4.5 mg
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Primary outcome
Weight change
Evidence
Moderate confidence
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
The AWARD-11 trial compared the effects of Dulaglutide 3.0 mg and 4.5 mg to 1.5 mg on body weight in patients with type 2 diabetes, finding significant weight reductions.
Clinical relevance
Weight management is crucial for patients with type 2 diabetes as it can improve glycemic control and reduce the risk of complications. The findings from this trial suggest that higher doses of Dulaglutide may offer a more effective option for weight loss, potentially leading to better overall health outcomes for patients.
Keep in mind
The study's population may not be representative of all patients with type 2 diabetes. Long-term effects and safety of higher doses were not assessed. The trial did not include a placebo group for comparison.
Published in
Journal Reference
Publication details and source links for this paper.
Enzo B, Juan PF, Francisco JT, et al. Dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes: AWARD-11 trial. Diabetes, Obesity & Metabolism. 2021;23(10):2242-2250. doi:10.1111/dom.14465
Save this study and add notes to your research library.
Main Effects
Dulaglutide 3.0 mg showed a weight decrease of 4.0 kg (p < 0.001).
Dulaglutide 4.5 mg resulted in a weight decrease of 4.7 kg (p < 0.001).
A higher proportion of patients achieved weight loss ≥5% with higher doses.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dulaglutide, Dulaglutiden dose and Activities of daily living, BMI, HbA1c, and 1 more.
This study contributes evidence to
Primary intervention
Dulaglutide
Primary outcomes
- Activities of daily living
- BMI
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
8
Evidence pairs
291
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
NoneDecrease
BMI
Dulaglutide → BMI
Dulaglutide → BMI
Evidence profile
NoneDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
HbA1c
Dulaglutide → HbA1c
Dulaglutide → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
StrongDecrease
Weight change
Dulaglutide → Weight change
Dulaglutide → Weight change
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
NoneIncrease
Activities of daily living
Dulaglutiden dose → Activities of daily living
Dulaglutiden dose → Activities of daily living
Evidence profile
NoneIncreasePatient-Reported
Unlock full evidence details
NoneDecrease
BMI
Dulaglutiden dose → BMI
Dulaglutiden dose → BMI
Evidence profile
NoneDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
HbA1c
Dulaglutiden dose → HbA1c
Dulaglutiden dose → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
StrongDecrease
Weight change
Dulaglutiden dose → Weight change
Dulaglutiden dose → Weight change
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Weight decreased by 3.1 kg with Dulaglutide 1.5 mg (p = 0.001).
- Significant BMI reductions were observed across all doses.
- HbA1c levels decreased significantly with higher doses.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients seeking weight management solutions.
Keep in Mind
- Results may not apply to all demographics or age groups.
- The study focused on short-term outcomes; long-term effects remain unknown.
- Individual responses to treatment may vary.
Between the Lines
- The study's population may not be representative of all patients with type 2 diabetes.
- Long-term effects and safety of higher doses were not assessed.
- The trial did not include a placebo group for comparison.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Dulaglutiden dose and HbA1c, Dulaglutiden dose and Body Weight.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Dulaglutiden dose Evidence Hub
All studies on Dulaglutiden dose
1 studies
intervention_hubContributes to Dulaglutiden dose evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
1 studies
outcome_hubMeasures HbA1c as a key outcome.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Dulaglutiden dose and HbA1c
Intervention: Dulaglutiden doseOutcome: HbA1c
1 results
All studies on Dulaglutiden dose and Weight change
Intervention: Dulaglutiden doseOutcome: Weight change
1 results
All studies on Dulaglutiden dose
Intervention: Dulaglutiden dose
1 results
All studies measuring HbA1c
Outcome: HbA1c
1 results
All studies measuring Weight change
Outcome: Weight change
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Moderate Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 48.9 | weak positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body weight?
Emerging Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Weight change
EvidenceScore™ Emerging | EvidenceScore™ 51.8 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body mass index?
Emerging Evidence
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 48.5 | weak positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve activities of daily living?
Emerging Evidence
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Activities of Daily Living.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Activities of daily living
EvidenceScore™ Limited | EvidenceScore™ 34.3 | neutral | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
GLP-1 agonists reduce heart fat thickness in diabetes.Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesDulaglutide may improve weight loss in obese patients with diabetesDietary supplements may lower diabetes risk in prediabetesHRS-7535 improves glycemic control in adults with type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.